Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma
Trang T T Nguyen, Enyuan Shang, Salveena Schiffgens, Consuelo Torrini, Chang Shu, Hasan Orhan Akman, Varun V Prabhu, Joshua E Allen, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin, Trang T T Nguyen, Enyuan Shang, Salveena Schiffgens, Consuelo Torrini, Chang Shu, Hasan Orhan Akman, Varun V Prabhu, Joshua E Allen, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Abstract
Purpose: Novel therapeutic targets are critical to unravel for the most common primary brain tumor in adults, glioblastoma (GBM). We have identified a novel synthetic lethal interaction between ClpP activation and HDAC1/2 inhibition that converges on GBM energy metabolism.
Experimental design: Transcriptome, metabolite, and U-13C-glucose tracing analyses were utilized in patient-derived xenograft (PDX) models of GBM. Orthotopic GBM models were used for in vivo studies.
Results: We showed that activation of the mitochondrial ClpP protease by mutant ClpP (Y118A) or through utilization of second-generation imipridone compounds (ONC206 and ONC212) in combination with genetic interference of HDAC1 and HDAC2 as well as with global (panobinostat) or selective (romidepsin) HDAC inhibitors caused synergistic reduction of viability in GBM model systems, which was mediated by interference with tricarboxylic acid cycle activity and GBM cell respiration. This effect was partially mediated by activation of apoptosis along with activation of caspases regulated chiefly by Bcl-xL and Mcl-1. Knockdown of the ClpP protease or ectopic expression of a ClpP D190A mutant substantially rescued from the inhibition of oxidative energy metabolism as well as from the reduction of cellular viability by ClpP activators and the combination treatment, respectively. Finally, utilizing GBM PDX models, we demonstrated that the combination treatment of HDAC inhibitors and imipridones prolonged host survival more potently than single treatments or vehicle in vivo.
Conclusions: Collectively, these observations suggest that the efficacy of HDAC inhibitors might be significantly enhanced through ClpP activators in model systems of human GBM.
Trial registration: ClinicalTrials.gov NCT04541082.
©2022 The Authors; Published by the American Association for Cancer Research.
Figures
References
- Wang LB, Karpova A, Gritsenko MA, Kyle JE, Cao S, Li Y, et al. . Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell 2021;39:509–28.
- Garofano L, Migliozzi S, Oh YT, D'Angelo F, Najac RD, Ko A, et al. . Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer 2021;2:141–56.
- Darmanis S, Sloan SA, Croote D, Mignardi M, Chernikova S, Samghababi P, et al. . Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep 2017;21:1399–410.
- Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, et al. . An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 2011;1:442–56.
- Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Gavriatopoulou M, Terpos E, Dimopoulos MA. Efficacy of panobinostat for the treatment of multiple myeloma. J Oncol 2020;2020:7131802.
- Wang J, Jiang J, Chen H, Wang L, Guo H, Yang L, et al. . FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma. Oncogene 2019;38:6737–51.
- Gryder BE, Wu L, Woldemichael GM, Pomella S, Quinn TR, Park PMC, et al. . Chemical genomics reveals histone deacetylases are required for core regulatory transcription. Nat Commun 2019;10:3004.
- Zhang Y, Ishida CT, Ishida W, Lo SL, Zhao J, Shu C, et al. . Combined HDAC and bromodomain protein inhibition reprograms tumor cell metabolism and elicits synthetic lethality in glioblastoma. Clin Cancer Res 2018;24:3941–54.
- Sanchez GJ, Richmond PA, Bunker EN, Karman SS, Azofeifa J, Garnett AT, et al. . Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 2018;46:1756–76.
- Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, et al. . Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell 2017;31:635–52.
- Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics 2017;9:59.
- Nguyen TTT, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, et al. . HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Invest 2020;130:3699–716.
- Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, et al. . The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget 2014;5:12728–37.
- Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. . Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013;5:171ra17.
- Bonner ER, Waszak SM, Grotzer MA, Mueller S, Nazarian J. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells. Neuro Oncol 2021;23:542–56.
- Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TTT, Kleiner G, et al. . Metabolic reprogramming by dual AKT/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma. Clin Cancer Res 2018;24:5392–406.
- Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, et al. . Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell 2019;35:721–37.
- Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, et al. . Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues. ACS Chem Biol 2019;14:1020–9.
- Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, et al. . ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia 2020;22:725–44.
- Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab 2020;32:341–52.
- Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS, et al. . A phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncol 2019;15:3189–96.
- Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, et al. . A phase I study of CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. Clin Cancer Res 2018;24:2060–73.
- Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, et al. . Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol 2017;18:770–8.
- Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, et al. . A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American brain tumor consortium study 03-03. Neuro Oncol 2011;13:509–16.
- Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. . Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 2015;21:827.
- Masui K, Harachi M, Cavenee WK, Mischel PS, Shibata N. mTOR complex 2 is an integrator of cancer metabolism and epigenetics. Cancer Lett 2020;478:1–7.
- Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer 2020;20:57–70.
- Gimple RC, Kidwell RL, Kim LJY, Sun T, Gromovsky AD, Wu Q, et al. . Glioma stem cell-specific superenhancer promotes polyunsaturated fatty-acid synthesis to support EGFR signaling. Cancer Discov 2019;9:1248–67.
- Chowdhry S, Zanca C, Rajkumar U, Koga T, Diao Y, Raviram R, et al. . NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature 2019;569:570–5.
- Randall EC, Lopez BGC, Peng S, Regan MS, Abdelmoula WM, Basu SS, et al. . Localized metabolomic gradients in patient-derived xenograft models of glioblastoma. Cancer Res 2020;80:1258–67.
- Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, et al. . Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 2016;126:1834–56.
- Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. . MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell 2017;32:71–87.
- Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, et al. . Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle 2018;17:468–78.
- Ralff MD, Kline CLB, Kucukkase OC, Wagner J, Lim B, Dicker DT, et al. . ONC201 demonstrates antitumor effects in both triple-negative and non-triple-negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. Mol Cancer Ther 2017;16:1290–8.
- Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, et al. . Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia 2018;20:80–91.
- Pruss M, Dwucet A, Tanriover M, Hlavac M, Kast RE, Debatin KM, et al. . Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma. Br J Cancer 2020;122:1146–57.
Source: PubMed